{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:04:24Z","timestamp":1793131464210,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijcard.2025.133384","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T15:07:53Z","timestamp":1747926473000},"page":"133384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["The efficacy and safety of dapagliflozin in pediatric heart failure"],"prefix":"10.1016","volume":"435","author":[{"given":"Swasthi S.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivdas","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harikrishnan","family":"Sivadasanpillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2022","key":"10.1016\/j.ijcard.2025.133384_bb0005","first-page":"e895","article-title":"AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2025.133384_bb0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2169\/internalmedicine.9632-22","article-title":"Efficacy of low-dose Dapagliflozin in young people with type 1 diabetes","volume":"62","author":"Urakami","year":"2023","journal-title":"Intern. Med."},{"key":"10.1016\/j.ijcard.2025.133384_bb0015","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300210","article-title":"The T2NOW study group, Dapagliflozin or Saxagliptin in pediatric type 2 diabetes","volume":"2","author":"Shehadeh","year":"2023","journal-title":"NEJM Evid."},{"key":"10.1016\/j.ijcard.2025.133384_bb0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(22)00052-3","article-title":"Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study","volume":"10","author":"Tamborlane","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ijcard.2025.133384_bb0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40272-024-00623-z","article-title":"Dapagliflozin and Empagliflozin in Paediatric indications: a systematic review","volume":"26","author":"Lava","year":"2024","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.ijcard.2025.133384_bb0030","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ekir.2021.12.019","article-title":"Efficacy and safety of Dapagliflozin in children with inherited Proteinuric kidney disease: a pilot study","volume":"7","author":"Liu","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ijcard.2025.133384_bb0035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00246-022-02983-0","article-title":"Early clinical experience with Dapagliflozin in children with heart failure","volume":"44","author":"Newland","year":"2023","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.ijcard.2025.133384_bb0040","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1001\/jama.296.15.1867","article-title":"Incidence, causes, and outcomes of dilated cardiomyopathy in children","volume":"296","author":"Towbin","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2025.133384_bb0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/ehf2.12082","article-title":"Association, heart failure from heart muscle disease in childhood: a 5\u201310 year follow-up study in the UK and Ireland","volume":"3","author":"Andrews","year":"2016","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ijcard.2025.133384_bb0050","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/dom.12638","article-title":"Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus","volume":"18","author":"Tirucherai","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ijcard.2025.133384_bb0055","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/psp4.12577","article-title":"Model-informed pediatric dose selection for Dapagliflozin by incorporating developmental changes","volume":"10","author":"Jo","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ijcard.2025.133384_bb0060","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/jama.298.10.1171","article-title":"Pediatric carvedilol study group, carvedilol for children and adolescents with heart failure: a randomized controlled trial","volume":"298","author":"Shaddy","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2025.133384_bb0065","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2125.2007.03046.x","article-title":"Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure","volume":"65","author":"Albers","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2025.133384_bb0070","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jacc.2024.02.017","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors in adults with congenital heart disease","volume":"83","author":"Neijenhuis","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2025.133384_bb0075","article-title":"Feasibility and safety of sodium glucose Cotransporter-2 inhibitors in adults with heart failure after the Fontan procedure","volume":"2022","author":"Muneuchi","year":"2022","journal-title":"Case Rep. Cardiol."},{"key":"10.1016\/j.ijcard.2025.133384_bb0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.32604\/chd.2024.056608","article-title":"Sodium-glucose cotransporter 2 inhibitors in adult and pediatric congenital heart disease: review of emerging data and future directions","volume":"19","author":"Marshall","year":"2024","journal-title":"CHD"},{"key":"10.1016\/j.ijcard.2025.133384_bb0085","article-title":"Experience with SGLT2 inhibitors in patients with single ventricle congenital heart disease and Fontan circulatory failure","author":"Konduri","year":"2023","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.ijcard.2025.133384_bb0090","doi-asserted-by":"crossref","DOI":"10.1007\/s00246-024-03604-8","article-title":"Dapagliflozin use in children with advanced heart failure undergoing heart transplantation: a matched case-control study","author":"Newland","year":"2024","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.ijcard.2025.133384_bb0095","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1161\/CIRCULATIONAHA.123.066605","article-title":"PANORAMA-HF investigators, Sacubitril\/valsartan in pediatric heart failure (PANORAMA-HF): a randomized, multicenter, double-blind trial","volume":"150","author":"Shaddy","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2025.133384_bb0100","unstructured":"Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing of Heart Failure Therapies, American College of Cardiology (n.d.). https:\/\/www.acc.org\/Latest-in-Cardiology\/Clinical-Trials\/2022\/12\/05\/14\/33\/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fClinical-Trials%2f2022%2f12%2f05%2f14%2f33%2fstrong-hf (accessed April 17, 2025)."},{"key":"10.1016\/j.ijcard.2025.133384_bb0105","first-page":"794","article-title":"Management of pediatric heart failure, Korean","volume":"54","author":"Dipchand","year":"2024","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2025.133384_bb0110","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/nep.13979","article-title":"Renoprotection with sodium-glucose cotransporter-2 inhibitors in children: knowns and unknowns","volume":"27","author":"Jiang","year":"2022","journal-title":"Nephrology"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325004279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325004279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:06:02Z","timestamp":1749009962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527325004279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":22,"alternative-id":["S0167527325004279"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.133384","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of dapagliflozin in pediatric heart failure","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.133384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"133384"}}